<DOC>
	<DOCNO>NCT01998412</DOCNO>
	<brief_summary>The study include patient treat Iluvien designate site European country market authorization grant order obtain broad safety usage information .</brief_summary>
	<brief_title>Iluvien Registry Safety Study</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<criteria>Any patient treat Iluvien protocol include study . Patients/Guardians unable understand sign Informed Consent exclude study . Retrospective Enrollment Criteria Patients treat ILUVIEN prior study initiation may include provide satisfy inclusion exclusion criterion , applicable , well , follow requirement : 1 . The site allow enroll patient treat ILUVIEN 36 month prior bring patient first study visit . 2 . The eligible patient must meet data requirement specify protocol , i.e. , baseline data collect within 7 day prior treatment ILUVIEN additional data subsequently collect approximately every 6 month thereafter enrolment study . 3 . The eligible patient must enrol least one year prior plan end study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>